文献速递淋巴瘤

PARP-1与HDAC抑制剂在皮肤T细胞淋巴瘤中的协同促凋亡作用经Blimp-1介导

The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.
PubMed 文献 · Blood Adv · 2020-01-01

本研究在蕈样肉芽肿(MF)小鼠模型中探讨PARP-1抑制剂talazoparib单用及联合HDAC抑制剂romidepsin的疗效。talazoparib通过p53上调导致G2/M细胞周期阻滞而杀伤MBL2细胞,体内实验证实其临床影响。联合romidepsin通过下调DNA修复基因FANCA、FANCD2、TOPBP1及经Blimp-1/Bax轴刺激凋亡产生协同细胞毒作用。

要点

  • talazoparib单药在MF小鼠模型中显示抗肿瘤活性,机制为p53上调致G2/M阻滞。
  • talazoparib联合romidepsin通过下调FANCA、FANCD2、TOPBP1及Blimp-1/Bax轴协同促凋亡。
  • 联合方案显示协同抗淋巴瘤效应,值得进一步临床试验研究。

核心结论

  • talazoparib与romidepsin联合在皮肤T细胞淋巴瘤中显示协同抗淋巴瘤效应,值得进一步临床研究。

研究设计与样本

  • 在蕈样肉芽肿(MF)小鼠模型中检测talazoparib的疗效,并在Moloney MuLV诱导的T细胞淋巴瘤(MBL2)细胞中进行体外实验。

主要发现

  • talazoparib对MBL2细胞的细胞毒作用通过p53上调导致G2/M细胞周期阻滞。
  • 体内实验证实talazoparib对MF肿瘤的临床影响。
  • talazoparib联合romidepsin通过下调FANCA、FANCD2、TOPBP1及经Blimp-1(PRDM1)/Bax轴刺激凋亡产生协同细胞毒作用。
  • romidepsin增加IRF8和Bcl-6表达,上调Blimp1和Bax;talazoparib通过上调IRF4上调Blimp-1和Bax,导致caspase 6和7剪切。

临床怎么用

  • PARP-1抑制剂talazoparib联合HDAC抑制剂romidepsin可能作为晚期MF的潜在治疗策略,但目前仅限临床前研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapy of advanced mycosis fungoides (MF) presents a therapeutic challenge, and the search for new therapeutic targets is ongoing. Poly(ADP-ribose) polymerase 1 was shown to be upregulated in patients with advanced MF and could be druggable by a new class of chemotherapeutic agents, PARP-1 inhibitors, which are already in clinical trials for other malignancies; however, the role of PARP-1 inhibitors in MF has never been established. We examined the efficacy of talazoparib in the murine model of cutaneous T-cell lymphoma. The cytotoxic effect of talazoparib on Moloney MuLV-induced T-cell lymphoma (MBL2) cells was a result of G2/M cell cycle arrest via the upregulation of p53. The in vivo experiments confirmed the clinical impact of talazoparib on MF tumors. When talazoparib was combined with the histone deacetylase (HDAC) inhibitor, romidepsin, the cytotoxic effect was synergized via downregulation of the DNA-repair genes Fanconianemia complementation group A (FANCA), Fanconi anemia complementation group D2 (FANCD2), and DNA topoisomerase II binding protein 1(TOPBP1)and stimulation of apoptosis via Blimp-1 (PRDM1)/Bax axis. Romidepsin increased the expression of IRF8 and Bcl-6, leading to upregulation of Blimp1and Bax; whereas talazoparib upregulated Blimp-1 and Bax via upregulation of interferon regulatory factor 4 (IRF4), leading to cleavage of caspases 6 and 7. Thus, a combination of talazoparib with romidepsin demonstrated the synergistic antilymphoma effect and warranted further investigation in a clinical trial.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kruglov O, Wu X, Hwang ST, et al. The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. Blood Adv. 2020. PMID: 33017467. doi:10.1182/bloodadvances.2020002049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。